Vivek Subbiah: Pan-KRAS inhibitors have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers.

Vivek Subbiah: Pan-KRAS inhibitors have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers.

According to Vivek Subbiah, Chief, Early-Phase Drug Development, Sarah Cannon Research Institute on LinkedIn:

“Pan-KRAS inhibitors, such as the one described here in Nature have broad therapeutic implications and merit clinical investigation in patients with KRAS-driven cancers. Such an exciting space.”

For the article click here.
Source: Vivek Subbiah/LinkedIn

cancer drug KRAS-driven cancers OncoDaily Oncology Pan-KRAS inhibitors Sarah Cannon Vivek Subbiah